Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis
Brief Summary: Tuberculosis is currently treated with a 6-month course regimen. During this time many patients might fail to adhere to treatment and default, increasing the risk of recurrent disease which might be multidrug resistant. A shorter duration of treatment is expected to provide improved patient compliance and at least equal or better clinical outcome. The aim of the trial is to evaluate the efficacy and safety of a gatifloxacin-containing regimen of four months duration for the treatment of pulmonary tuberculosis,


Options:
A: Arm Label: Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Arm Label: Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Arm Label: Drug Sensitive: Rifafour; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifafour | Arm Label: Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Intervention Type: DRUG; Name: Moxifloxacin (M); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Pretomid (Pa); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Pyrazinamide (Z); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Rifafour; Assigned to Arm(s): Drug Sensitive: Rifafour
B: Arm Label: Cohort 1, Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 1, Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 1, Sequence 3; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 2, Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 2, Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 2, Sequence 3; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Sequence 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Sequence 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Sequence 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2, Sequence 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2, Sequence 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2, Sequence 3
C: Intervention Type: DRUG; Name: Gatifloxacin combined regimen; Assigned to Arm(s): N/A
D: Arm Label: TMC207 Stage 1; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: TMC207 Stage 2; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Intervention Type: DRUG; Name: TMC207; Assigned to Arm(s): TMC207 Stage 1, TMC207 Stage 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2 | Intervention Type: DRUG; Name: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis); Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2, TMC207 Stage 1, TMC207 Stage 2

Answer: C